Astrazeneca PLC (NYSE:AZN) was upgraded by analysts at Liberum Capital from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

A number of other analysts have also recently issued reports on the stock. Cantor Fitzgerald restated a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, October 28th. Citigroup Inc. restated a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, September 23rd. Berenberg Bank restated a “buy” rating on shares of Astrazeneca PLC in a research note on Sunday, September 11th. Bank of America Corp. set a $41.00 target price on shares of Astrazeneca PLC and gave the stock a “buy” rating in a research note on Tuesday, October 4th. Finally, Beaufort Securities restated a “hold” rating on shares of Astrazeneca PLC in a research note on Friday, August 26th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. Astrazeneca PLC has a consensus rating of “Buy” and an average target price of $37.61.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

Shares of Astrazeneca PLC (NYSE:AZN) traded up 2.35% during mid-day trading on Friday, reaching $26.99. 4,096,609 shares of the company’s stock traded hands. The stock has a market cap of $68.28 billion, a PE ratio of 27.70 and a beta of 0.83. The firm has a 50 day moving average price of $29.20 and a 200-day moving average price of $30.75. Astrazeneca PLC has a 12 month low of $25.88 and a 12 month high of $35.04.

Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, November 10th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.58. The company earned $5.70 billion during the quarter, compared to analysts’ expectations of $5.95 billion. Astrazeneca PLC had a net margin of 10.35% and a return on equity of 31.30%. Astrazeneca PLC’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same quarter last year, the company posted $1.03 EPS. On average, analysts predict that Astrazeneca PLC will post $3.02 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. AMP Capital Investors Ltd increased its stake in Astrazeneca PLC by 205.9% in the first quarter. AMP Capital Investors Ltd now owns 73,409 shares of the company’s stock valued at $2,079,000 after buying an additional 49,409 shares in the last quarter. Royal Bank of Canada increased its stake in Astrazeneca PLC by 24.2% in the first quarter. Royal Bank of Canada now owns 722,283 shares of the company’s stock valued at $20,339,000 after buying an additional 140,921 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in Astrazeneca PLC by 3.1% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 34,217 shares of the company’s stock valued at $964,000 after buying an additional 1,027 shares in the last quarter. Logan Capital Management Inc. increased its stake in Astrazeneca PLC by 0.6% in the first quarter. Logan Capital Management Inc. now owns 19,698 shares of the company’s stock valued at $554,000 after buying an additional 109 shares in the last quarter. Finally, First Republic Investment Management Inc. increased its stake in Astrazeneca PLC by 14.9% in the first quarter. First Republic Investment Management Inc. now owns 134,932 shares of the company’s stock valued at $3,800,000 after buying an additional 17,480 shares in the last quarter. Institutional investors and hedge funds own 11.81% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Liberum Capital Upgrades Astrazeneca PLC (AZN) to “Buy”” was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this report on another publication, it was copied illegally and republished in violation of international copyright & trademark legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2016/11/25/liberum-capital-upgrades-astrazeneca-plc-azn-to-buy.html.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

5 Day Chart for NYSE:AZN

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.